Parkinson Disease

Considerable discrepancy found between overt clinical symptoms of laryngeal pathology and abnormalities observed during a task protocol.

The Patient Controller will join a growing list of Abbott digital care products aimed at streamlining the therapeutic experience.

The new approval is based on the result of 38 clinical trials involving more than 1000 patients.

Impulse control disorder symptoms also commonly found in Parkinson disease patients treated with dopamine agonists.

Study data suggested that up to 80% of patients with Parkinson disease may have ophthalmologic symptoms.

New drug more often linked to a full ON response from Parkinson disease patients at 30 minutes when compared to a placebo.

Patients in the treatment group had improved dyskinesia symptoms and off time.

A multifaceted care plan for patients is shown to improve both their quality of life and the burden of treatment for caregivers.

Investigators will move forward with a phase 2 study testing AV-101 as a potential treatment for patients with Parkinson disease receiving levodopa-based therapy.

The approval expands options for patients with Parkinson disease to tailor treatment to their unique needs.

Of the 176 adverse events found in a trial targeting ambroxol as a Parkinson disease drug, only 3 were deemed related to the treatment.

In a study based in Finland, investigators link different types of oral antibiotics to an increased risk of Parkinson disease.

A pair of surveys show the majority of patients suffering from Parkinson disease would be willing to take CBD to manage psychosis symptoms if it is proven safe and effective.

Higmark Interactive will now be able to market their full suite of EQ software modules.

Investigators submit recommendations for physicians for Parkinson disease reflecting recent advancements, including a new section on palliative care.

A new FDA approval allows istradefylline to be taken as an add-on with other medication to reduce the time medication does not work in Parkinson disease patients.

As part of the Parkinson’s Progression Markers Initiative, researchers announce the addition of RNA sequencing dataset.

Survey responses from 700 Parkinson disease patients and their caregivers show a majority of patients report problems with non-motor symptoms.

Both motor and non-motor symptoms improve using ear stimulation can help manage Parkinson symptoms.

Intec Pharma announces clinical trial failure after finding new drug did not have a market difference treating PD from existing medications.

A new study shows that loss of phosphodiesterase, not just dopamine, indicates a worsening of motor symptoms in patients with Parkinson disease.

A new meta-analysis determined DBS is equally useful for patients with Parkinson’s who have related mutations.

In a study presented at Digestive Disease Week 2019, results indicated the risk of developing Parkinson's disease was 3 times higher in patients who had appendectomies.

A tear-based biomarker for Parkinson disease would allow providers to diagnose the condition sooner and create a measurement tool for new drug development.

Identifying a potential biomarker is an extended process, one which benefits from collaboration between researchers and clinicians of many specialties.

Investigators examined both basal and reflex tears from patients with and without Parkinson disease, in search of a potential biomarker.

It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

Investigators found that mindfulness yoga group can be an effective treatment option for patients with PD to manage both stress and symptoms.

The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant.